Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response.
Local nasal immunotherapy (LNIT) was administered in a double-blind study to 67 subjects. Twenty-three received an unmodified ragweed extract (RW), 24 received a glutaraldehyde polymer of ragweed extract (PRW), and 21 received placebo. Serum ragweed-specific IgE (S-IgE), ragweed-specific nasal secretory (NS-) IgE, secretory IgA (SIgA) and IgG, and NS-albumin were measured. RW therapy caused a significant increase in ragweed-specific S-IgE (p less than 0.005) and NS-SIgA (p less than 0.05). PRW therapy caused a significant rise in ragweed-specific NS-SIgA (p less than 0.001). NS-IgE (p less than 0.05), and NS-IgG (p less than 0.01). Ragweed-specific S-IgG was not affected by any of the treatments. There was no consistent correlation between NS-antibody levels and symptom/medication scores.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis / Q000276:immunology; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010919:Placebos; D011058:Pollen / Q000008:administration & dosage; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000628:therapy
D000888:Antibodies, Anti-Idiotypic; D010919:Placebos; D007073:Immunoglobulin E